Search research articles

Search research articles

Related Experiment Videos

Pegaspargase: an alternative?

¹Baptist Medical Center, San Antonio, TX 78205, USA.

The Annals of Pharmacotherapy

|May 1, 1997

Summary

This summary is machine-generated.

Pegaspargase offers a safe and effective alternative to L-asparaginase for patients with hypersensitivity. This modified drug, polyethylene glycol (PEG) asparaginase, reduces immune response and extends half-life in acute lymphocytic leukemia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.

Bone marrow transplantation·2004

Same author

Valproate in status epilepticus.

The Annals of pharmacotherapy·1995

Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026

Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026

Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026

Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026

Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026

Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026

See all related articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Area of Science:

Oncology
Pharmacology

Background:

L-asparaginase is crucial for acute lymphocytic leukemia treatment.
Hypersensitivity reactions limit L-asparaginase efficacy.
Pegaspargase (PEG-asparaginase) is a modified form of L-asparaginase.

Purpose of the Study:

To review pegaspargase (PEG-asparaginase) for its chemistry, pharmacology, pharmacokinetics, clinical activity, adverse effects, and administration.
To evaluate pegaspargase as an alternative for patients with L-asparaginase hypersensitivity.

Main Methods:

Comprehensive literature search (MEDLINE, CANCERLIT, CURRENT CONTENTS) from 1980-1996.
Inclusion of articles providing critical information not readily available.
Focus on pegaspargase, PEG-asparaginase, and Oncaspar.

Related Experiment Videos

Main Results:

Pegaspargase (polyethylene glycol conjugated L-asparaginase) demonstrates an altered immune response tendency and extended half-life.
Most patients with hypersensitivity to native L-asparaginase tolerate pegaspargase.
Adverse effects of pegaspargase are comparable to native L-asparaginase.
Recommended dosage: 2500 IU/m2 every 2 weeks via IM or IV injection.

Conclusions:

Pegaspargase is a safe and effective alternative for patients experiencing hypersensitivity to both E. coli- and E. carotovora-derived L-asparaginase.
Pegaspargase should not be routinely substituted for L-asparaginase.